Special report on the deposit and use of Chongqing Lummy Pharmaceutical Co.Ltd(300006) raised funds
Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Special report on the deposit and use of raised funds in 2021
In accordance with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the self discipline supervision of listed companies No. 2 – standardized operation of companies listed on the gem issued by the CSRC, the company will make a special explanation on the deposit and use of raised funds in 2021 as follows:
1、 Availability of raised funds
According to the reply on Approving the registration of Chongqing Lummy Pharmaceutical Co.Ltd(300006) issuing shares to specific objects (zjxk [2021] No. 437) issued by China Securities Regulatory Commission, the company reported to Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) Nanning Zhongheng Tongde pharmaceutical industry investment fund partnership (limited partnership) and Guangxi guangtou Guohong health industry fund partnership (limited partnership) issued 24367000 ordinary shares (A shares) in total, with a par value of 1.00 yuan per share and an issue price of 4.45 yuan / share. The total amount of funds actually raised was 108433150000 yuan. After deducting various issuance expenses of 1981560459 yuan, The net amount of funds raised is RMB 106451589541 (hereinafter referred to as “funds raised by issuing shares to specific objects in 2021”).
The above raised funds were received on March 2, 2021. The availability of the raised funds has been verified by Sichuan Huaxin (Group) Certified Public Accountants (special general partnership) and issued the capital verification report “Chuan Hua Xin Yan (2021) No. 0021”.
2、 Use and balance of raised funds
1. Non public offering of shares in 2021
As of December 31, 2021, the use and balance of funds raised by the company’s issuance of shares to specific objects in 2021 are as follows (monetary unit: RMB):
Project amount
Actually transferred into the raised funds of the company [Note 1] 106606652750
Less: 96397824673 directly invested in the raised project funds
Other issuance expenses paid: 155063209
Plus: net interest income deducting handling charges 487604384
Balance of special account for raised funds 10541369252
[Note 1]: the total amount of funds raised by the company from the issuance of shares to specific objects is 108433150000 yuan. Sinolink Securities Co.Ltd(600109) has remitted the balance of 106606652750 yuan after deducting the recommendation and underwriting fee of 1826497250 yuan (excluding tax) into the special account for raised funds opened by the company on March 2, 2021.
2. As of December 31, 2021, the deposit of funds raised by non-public offering of the company in 2021 is shown in the following table (monetary unit: RMB):
Opening bank account number, account category and purpose year-end balance
Special report on the deposit and use of Chongqing Lummy Pharmaceutical Co.Ltd(300006) raised funds
Hua Xia Bank Co.Limited(600015) Chongqing 112830 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 2978 current account 541363393 Liangjiang Jinkai sub branch supplementary working capital
Hua Xia Bank Co.Limited(600015) Chongqing 112830 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 3234 certificate of deposit account [note] gold 10000000000 Liangjiang Jinkai sub branch
Shanghai Pudong Development Bank Co., Ltd. 8 Dalian Demaishi Precision Technology Co.Ltd(301007) 88015 Shenzhen Capstone Industrial Co.Ltd(000038) 81 current account repayment of loan 58.59 Company Chongqing Branch
Total 10541369252
Note: according to the tripartite supervision agreement on raising funds by issuing shares to specific objects signed by the company, Hua Xia Bank Co.Limited(600015) Chongqing branch and Sinolink Securities Co.Ltd(600109) Chongqing Branch, the company deposited 330 million yuan of raised funds in the special account of Hua Xia Bank Co.Limited(600015) raised funds in the form of certificate of deposit. During the reporting period, the company transferred the raised funds from the certificate of deposit account to the special current account according to the needs of business activities, and used them to supplement working capital. By the end of 2021, the balance of the certificate of deposit account was 100 million yuan.
2、 Management of raised funds
In order to standardize and strengthen the management and use of raised funds and protect the legitimate rights and interests of investors, the company has formulated the raised funds management system in accordance with the provisions and requirements of relevant laws, regulations and normative documents. After the funds raised by this offering were received, the company hired a capital verification institution to verify the availability, and timely signed a supervision agreement on the raised funds with the sponsor and the relevant special account storage bank, so as to supervise the management and use of the raised funds and ensure the special use of the special funds.
3、 Actual use of raised funds this year
The comparison table of the company’s use of raised funds in 2021 is detailed in the annex to this report.
4、 Change the use of funds for investment projects with raised funds
As of December 31, 2021, the company has not changed the investment projects of the raised funds by issuing shares to specific objects in 2021.
5、 Use and disclosure of raised funds
The company uses the raised funds in strict accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for self discipline supervision of listed companies No. 2 – standardized operation of GEM listed companies and other relevant laws and regulations, as well as the provisions and requirements of relevant laws and regulations of the CSRC and the management system of raised funds, and timely Truthfully, accurately and completely perform relevant information disclosure, and there is no illegal use of raised funds.
Annex 1: comparison table of the use of funds raised by issuing shares to specific objects in 2021
Chongqing Lummy Pharmaceutical Co.Ltd(300006) March 24, 2022
Comparison table of the use of funds raised from specific stock issuers in 2026
